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Abstract
Patientswithchronickidneydisease(CKD)haveahighbur-
den of mortality and cardiovascular morbidity. Additional
strategies to modulate cardiovascular risk in this popula-
tion are needed. Anaemia has been associated with adverse
outcomes in CKD populations, and the ability to modify
this parameter with the use of erythropoiesis-stimulating
agents has been a topic of much debate. Data on the effects
of anaemia correction on cardiovascular outcomes and sur-
vival in CKD have been both discordant and controversial.
It is hoped that the ongoing Trial to Reduce cardiovascu-
lar Events with Aranesp Therapy (TREAT) will help to
redress the current clinical gaps and the uncertainty over
the optimal management of anaemia in patients with CKD
and type 2 diabetes mellitus. Anaemia is also increasingly
being recognized as an important comorbid condition in
patients with symptomatic heart failure. The ongoing Re-
duction of Events with Darbepoetin alfa in Heart Failure
(RED-HFTM) trial is designed to determine whether the
treatment of anaemia improves outcomes in such patients.
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Use of erythropoiesis-stimulating agents in the
treatment of anaemia in patients with chronic
kidney disease
Chronic kidney disease (CKD) appears to have a major im-
pact on the risk of mortality and major non-fatal cardiovas-




and hospitalization among patients with CKD. Anaemia
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is now also recognized as a risk factor for CVD in pa-
tients with CKD, for worse outcomes in CKD patients with
existingCVD,andforprogressionofCKD[1,2].Whilenew
therapeutic strategies are needed to address the burden of
CVDinpatientswithCKD,definitiveevidencedemonstrat-
ing that treatment of anaemia can improve cardiovascular
outcomes has not yet been provided by any prospective
clinical trial.
Lack of evidence for benefit to CVD with full
anaemia correction
The impact of normalization of haematocrit versus a
lower haematocrit on mortality and non-fatal cardiovascu-
lar events in patients on haemodialysis was first tested in a
large, randomized, open-label trial, the Normal Hematocrit
Treatment trial [3]. The study enrolled only haemodialy-
sis patients with clinical evidence of chronic heart failure
(CHF) or ischaemic heart disease, half of whom had dia-
betes. The median duration of treatment was 14 months,
target haematocrit was 42 ± 3% [haemoglobin (Hb)
14 ± 1 g/dL] in the normal haematocrit group and
30 ± 3% (Hb 10 ± 1 g/dL) in the low-haematocrit group,
and the primary endpoint was the length of time to death or
first non-fatal myocardial infarction. Although not statisti-
callysignificant,ratesofdeathorfirstnon-fatalmyocardial
infarction were higher in patients in the normal haemat-
ocrit group compared with the low haematocrit group, with
a relative risk of 1.3 [95% confidence interval (CI) 0.9–
1.9] (Figure 1). This trial was terminated prematurely when
the Data Safety Monitoring Committee concluded that the
trial would be unable to reach its pre-stated endpoint of
demonstrating improved outcomes in the normal haemat-
ocrit group, although it has been suggested that the study
population was affected by too many comorbidities to ben-
efit from full anaemia correction [4].
In the Canadian multicentre study in CKD, no associa-
tion could be made between Hb level and left ventricular
mass index (LVMI) when anaemia was prevented and/or
corrected by immediate versus delayed treatment with epo-
etin [5]. While active treatment led to a sustained differ-
ence in Hb levels between study groups in the 152 patients
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Fig. 1. Probability of death or a first non-fatal myocardial infarction
in both patient groups in the Normal Haematocrit Treatment trial [3]
( C   1998 Massachusetts Medical Society). All rights reserved.
eligible for analysis, there was no statistically significant
difference between groups for the primary outcome of the
mean change in LVMI from baseline to 24 months (Fig-
ure 2) suggesting that active treatment of anaemia with
epoetin in CKD patients had no effect on the change in
LVMI or growth.
A lack of beneficial cardiac effect with Hb normaliza-
tion was also evident in the Canadian–European Normal-
izationstudyin596incidenthaemodialysispatientswithout
symptomatic cardiac disease or left ventricular dilation [6].
WhileHbtargetswereachievedwithepoetintreatmentover
24 weeks, and maintained for an additional 72 weeks, the
percentage changes in left ventricular volume index and
LVMI between baseline and last recorded value were not
significantly different between the two groups.
A more recent retrospective observational study of
5848haemodialysispatientsinvestigatedwhethertherewas
any association between predialysis use of erythropoiesis-
stimulating agents (ESAs) in the treatment of anaemia of
CKD and postdialysis cardiovascular outcomes [7]. While
the data suggested that the risk of developing a cardio-
vascular event was significantly lower in patients who
received ESA treatment prior to dialysis compared with
ESA-untreated patients [relative risk (RR) 0.70 (95% CI,
0.61–0.82)], it is not possible to conclude whether such
improvements in cardiovascular outcomes are due to im-
proved Hb levels resulting from ESA therapy, or because
of the higher rates of concomitant medication use in the
ESA-treated patients, compared to the untreated patients.
Large-scale studies on the impact of anaemia
therapy
The need for new randomized clinical trials to address crit-
ical knowledge deficits, particularly with regard to the im-
pact of anaemia therapy on CVD and survival, has previ-
ously been recognized [8,9].
Two large-scale studies evaluated the effect of differ-
ent levels of anaemia correction on treatment with ESAs
on cardiovascular morbidity and mortality in patients with
CKD [10,11], while another large-scale study is ongoing to
Fig. 2. Mean Hb levels (A) and mean LVMI (B) in both patient groups in
theCanadianmulticentrestudyinCKD.LVMI,leftventricularmassindex.
Reprinted from [5], Copyright (2005), with permission from Elsevier.
determineifthereisamorbidityandmortalitybenefittoan-
aemia treatment with ESAs in this patient population [1,2].
The Cardiovascular risk Reduction by Early Anaemia
Treatment with Epoetin beta (CREATE) trial investigated
theeffectofearlyanaemiacorrectiononcardiovascularrisk
inalargesampleofpatientswithmild-to-moderateanaemia
(defined as Hb 11.0–12.5 g/dL at the time of the study) and
CKD not yet requiring renal replacement therapy [10]. In
this multicentre, open-label, parallel-group study, 603 pa-
tients were randomized to receive early or late treatment
with epoetin. The primary endpoint was time to cardio-
vascular event. The early treatment group started epoetin
therapy immediately, aiming for a target Hb level of 13–
15 g/dL. The late or routine treatment group started epoetin
therapy once theHblevel had decreased tobelow10.5g/dL
(target Hb level 10.5–11.5 g/dL). During the 3-year study,
early and complete correction of anaemia did not reduce
the risk of cardiovascular events compared with partial cor-
rection although there was a significant improvement in all
major quality of life scores in the treatment group aiming
for the higher target Hb level. A major limitation of the
study was that the rate of cardiovascular events was consid-
erably lower than anticipated. Consequently, CREATE was
underpowered to demonstrate a difference between the two
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In the Correction of Hemoglobin and Outcomes in Re-
nal insufficiency (CHOIR) study, a total of 1432 patients
not receiving dialysis were randomly assigned to receive
epoetin doses targeted to achieve a Hb level of 13.5 g/dL
(high Hb group) or 11.3 g/dL (low Hb group) [11]. The pri-
maryendpointwastimetodeathorcardiovascularendpoint.
CHOIR showed a 34% increased risk of complications and
deathfromcardiovascularcausesinthehighHbgroup[11].
The study was terminated by a Data and Safety Monitoring
Board at a mean and median follow-up of 16 months, when
it was determined that the likelihood of demonstrating a
benefit for the high Hb level was <5%. However, a num-
ber of concerns about the study remain, including the high
patient dropout rate, the imbalance in baseline character-
istics between treatment arms, the doses of epoetin used
and the fact that the protocol was changed with regard to
target Hb levels after around one-third of the cohort had
been randomized.
CREATE and CHOIR are the largest cardiovascular out-
comes studies in non-dialysis CKD patients published to
date.BothtestedthehypothesisthathigherHblevelswould
lead to improved patient outcomes; however, in contrast
to expectations, the results from both studies were neg-
ative. These trials have helped to focus on the need for
appropriately designed randomized, double-blind, placebo-
controlled trials, but have not sufficiently determined the
effect of anaemia therapy on cardiovascular outcomes in
patients with CKD. This effect, therefore, needs to be rig-
orously tested in a robust randomized clinical trial. The on-
going Trial to Reduce cardiovascular Events with Aranesp
Therapy (TREAT) is a 4000-patient, multicentre, double-
blind,randomized,placebo-controlledphaseIIIclinicaltrial
[1] in which the objectives are fundamentally different to
those of CREATE and CHOIR [2]. CREATE and CHOIR
aimed to determine the impact of early versus late anaemia
correction or degree of anaemia correction, respectively,
on mortality and cardiovascular morbidity in patients with
CKD. TREAT, however, aims to determine the impact of
no anaemia intervention with an ESA (placebo) versus
anaemia intervention with darbepoetin alfa, a long-acting
ESA, on mortality and non-fatal cardiovascular events in
anaemic patients with CKD and type 2 diabetes mellitus.
Subjects are randomized 1:1 to either darbepoetin alfa ther-
apy (to achieve and maintain a target Hb level of 13 g/dL)
or placebo control (to maintain Hb levels ≥9g / d L ) .T h e
placebo arm permits rescue therapy with darbepoetin alfa
whenHblevelsare<9g/dLuntiltheHblevelisagain≥9g/
dL, when placebo will resume. TREAT is event driven and
has a composite primary endpoint of death or the devel-
opment of myocardial infarction, myocardial ischaemia,
stroke or CHF. The components of the composite primary
endpoint were chosen for their clinical importance and an-
ticipated response to anaemia therapy. The clinical end-
pointsinTREATwillbekeyfactorsindeterminingthecost
effectiveness of, and ultimately access to, anaemia thera-
pies in CKD. It is hoped that the study will provide data
that are critical to the evolution of cardiovascular risk man-
agement in this high-risk population. Enrolment in TREAT
was completed in December 2007, with 4047 patients ran-
domized, meaning that TREAT has enrolled more patients
than CHOIR and CREATE combined.
PublicationoftheresultsfromCREATEandCHOIRand
a large meta-analysis [12] generated much discussion and
controversy in the field. This led to recent reviews of the
safetyofESAsinCKDpatientsbytheEuropeanMedicine’s
Agency(EMEA)andtheUSFoodandDrugAdministration
[FDA; the cardiovascular and Renal Drugs Advisory Com-
mittee (CRDAC) and Drug Safety and Risk Management
Advisory Committee (DSRMAC)]. The EMEA concluded
that‘...thebenefitsoftheseproductscontinuetooutweigh
risks in the approved indications...’ .B a s e do np o s i t i v e
opinions granted for all centrally authorized ESAs in the
European Union by the EMEA’s Committee for Medici-
nal Products for Human Use, and a recent public statement
[13], the European Commission has approved updates to
the prescribing information. These include a new uniform
target Hb range of 10–12 g/dL, with a warning not to ex-
ceed a concentration of 12 g/dL. Following a joint meeting
on 11 September 2007, the CRDAC and DSRMAC (of the
FDA) also recommended that ESA dosing should be in-
dividualized to achieve and maintain Hb levels within the
range of 10–12 g/dL. After careful and regular review of
the safety data from TREAT, in March 2008 the Data Mon-
itoring Committee (DMC) for the ongoing study, for which
the target Hb level in the darbepoetin alfa treatment arm is
13 g/dL, have found no evidence to suggest alteration or
termination of the trial.
Limitations in the data supporting anaemia management
guidelinesforpatientswithCKDunderscoreacriticalpoint
that guidelines should be dynamic documents, evolving as
new and better data become available and stimulating clini-
cal investigation by identifying gaps in current knowledge.
While CHOIR and CREATE had their limitations, it is
hoped that TREAT will provide the conclusive data needed
to guide anaemia management in this high-risk population.
Use of ESAs in the early treatment of anaemia
in CHF
There is great concern over the devastating impact of CVD
during the early stages of CKD on the long-term clinical
outcome of patients. This underlines the concept that man-
agementofpatientswithCKDshouldbefocusedmainlyon
strategies that aim to prevent the development of cardiovas-
cular complications. Anaemia has been demonstrated to be
a common, comorbid condition in patients with CHF, and
a growing body of literature from observational databases
and clinical trials suggests that anaemia is an independent
risk factor for adverse outcomes in patients with heart fail-
ure [14,15]. This relationship persists whether considering
Hb concentration as a continuous variable or anaemia as a
categorical variable.
IntheCOMETstudy,Komajdaandcolleagues[16]mea-
sured the impact of new-onset anaemia on morbidity and
mortalityin3029CHFpatientsreceivingbetablockers.Re-
sults showed that RR of all-cause mortality (RR 1.47; P <
0.0001), death or hospitalization (RR 1.28; P <0.0001), or
hospitalization for heart failure (RR 1.43; P < 0.0001) was
higher for anaemic patients than for non-anaemic patients.
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whose Hb decreased from baseline over the course of the
study [decrease of >3 g/dL (RR 3.37; P < 0.0001) or de-
crease of 2–3 g/dL (RR 1.47; P = 0.011)] than in patients
whose Hb increased 0–1 g/dL from baseline, highlighting
the importance of adequate Hb control in these patients.
Anaemia is increasingly being recognized as an impor-
tantcomorbidconditioninitsownright,andonethatshould
be treated in patients with heart failure.
ESAs have become a mainstay in the treatment of
anaemia in patients with CKD, and phase II studies di-
rectly examining the effect of ESA therapy on clinical out-
comesinpatientswithCHFhavebeenpublished.Silverberg
et al. [17,18] have described benefits in several studies af-
ter the correction of anaemia in patients with CHF. One
of their earlier investigations was a small, randomized,
controlled trial of epoetin and intravenous (i.v.) iron in
patients with moderate-to-severe CHF [17]. Thirty-two pa-
tientswithNewYorkHeartAssociation(NYHA)functional
class III to IV heart failure who had a left ventricular ejec-
tionfraction(LVEF)of≤40%(despitemaximallytolerated
doses of medications for CHF) and whose Hb levels were
persistently between 10.0 and 11.5 g/dL were randomized
into two groups. Group A received subcutaneous (s.c.) epo-
etinandi.v.irontoincreasethelevelofHbtoatleast12.5g/
dL, while group B received no treatment for anaemia. A
marked improvement in cardiac and patient function was
observed in the treated group. The mean NYHA class im-
proved by 42.1% in group A and worsened by 11.4% in
group B. LVEF increased by 5.5% in group A and de-
creased by 5.4% in group B. The number of days spent
in hospital compared with the same period of time before
entering the study decreased by 79.0% in group A and in-
creased by 57.6% in group B. A subsequent report by the
same group described its findings in a series of 78 con-
secutive patients with symptomatic CHF and anaemia (Hb
level<12.0g/dL)treatedwithepoetinand,whennecessary,
i.v. iron sucrose [18]. Over a mean observation period of
20.7 ±12.1 months, mean Hblevels increased from10.2±
1.1 to 13.5 ± 1.2 g/dL (P < 0.01). NYHA functional class
and LVEF were significantly improved, and the number of
hospitalizations was significantly reduced compared with
the period before treatment (all P < 0.01).
Anumberofsmall-scalestudieshaveexaminedtheeffect
of the longer-acting ESA, darbepoetin alfa, in the treatment
of anaemia in CHF patients on various clinical outcomes.
vanVeldhuisenetal.[19]conductedamulticentre,random-
ized, double-blind, placebo-controlled study to evaluate the
effect of darbepoetin alfa on Hb levels and clinical effects
in anaemic patients (defined as Hb 9–12.5 g/dL) with CHF.
Patients [mean (standard deviation; SD) age 71 [11] years]
received placebo (n = 55) or s.c. darbepoetin alfa, admin-
istered every 2 weeks for 26 weeks to a target Hb level
of 14 ± 1.0 g/dL. Patients in the darbepoetin alfa treat-
ment group received either a starting weight-adjusted dose
of 0.75 μg/kg (n = 56) or a fixed dose of 50 μg( n =
54). As expected, mean (SD) Hb rise from baseline [11.5
(0.7) g/dL] in the two darbepoetin alfa treatment groups
was greater than in the placebo group (+1.87 ± 1.36 g/dL
and +1.64 ± 0.98 g/dL, respectively, versus +0.07 ± 1.08
g/dL).Followingtreatmentwithdarbepoetinalfa,therewas
also a significant improvement in Kansas City Cardiomy-
opathy Questionnaire (KCCQ) total symptom score (8.2
versus 1.5 points; P = 0.027). In addition, non-significant
improvements were seen in the combined darbepoetin alfa
group versus the placebo group for the 6-min walk test
(6MWT; P = 0.074) and the Patient’s Global Assessment
Score (P = 0.057).
In another multicentre, randomized, double-blind,
placebo-controlled trial, Ponikowski and colleagues set out
toinvestigatewhethertreatmentwithdarbepoetinalfaleads
to improvements in exercise capacity in anaemic patients
with symptomatic CHF [20]. Patients received placebo
(n = 22) or s.c. darbepoetin alfa (n = 19), at a starting
dose of 0.75 μg/kg administered every 2 weeks for 26
weeks. Darbepoetin alfa raised Hb levels [+1.5 g/dL (95%
CI; 0.5–2.4; P = 0.005)] and enabled significant increases
in exercise duration [+108 seconds (95% CI; −11 to 228;
P = 0.075)], compared with patients in the placebo group.
Patients receiving darbepoetin alfa also showed a signifi-
cant improvement in self-reported Patient’s Global Assess-
ment of Change (79% versus 41%; P = 0.01) compared
with patients receiving placebo.
The effects of darbepoetin on quality of life and emo-
tionalstressinCHFpatientswithanaemiawereinvestigated
by Kourea and colleagues [21]. Forty-one CHF patients
(NYHA functional classes II and III) who were receiving
optimal medical treatment, with a documented LVEF of
<40%, Hb <12.5 g/dL and a serum creatinine of <2.5 μg/
dL, were included in a single-blind study. None of the
patients had received erythropoietin treatment within the
previous 6 months. The patients were randomized (1:1)
to receive either s.c. darbepoetin alfa 1.5 μg/kg every 20
days (n = 21) or placebo (0.9% normal saline) (n = 20)
for 3 months. Both groups received iron sulphate (250 μg
twice daily). A whole blood count was performed every
15 days; if Hb exceeded 14 g/dL in patients receiving dar-
bepoetin alfa, therapy was withdrawn for the following
15 days and started again if Hb fell below 12.5 g/dL.
Electrocardiographic LVEF, exercise capacity [6MWT and
plasma b-type natriuretic peptide (BNP)], quality of life
[KCCQ and Duke’s Activity Status Index (DASI)] and psy-
chological status [Beck Depression Inventory (BDI) and
20-item Zung Self-rating depression Scale (Zung SDS)]
were assessed at baseline and post-treatment.
A significant post-treatment improvement was seen in
thefollowingparametersinthedarbepoetinalfagrouponly:
LVEF [32 ± 6% (from 26 ± 6%); P < 0.001]; Hb [12.8 ±
1.4g/dL(from10.9±1.0g/dL);P<0.001];6MWT[274±
97 m (from 201 ± 113 m); P < 0.01]; plasma BNP [517 ±
579 pg/mL (from 829 ± 858 pg/mL); P = 0.002].
KCCQ functional [78 ± 14% (from 57 ± 24%); P <
0.01] and KCCQ overall [68 ± 20% (from 47 ± 22%);
P < 0.001], DASI [19 ± 11 (from 14 ± 9); P < 0.05],
Zung SDS [38 ± 10 (from 47 ± 11); P < 0.05] and BDI
[11 ± 9 (from 16 ± 10); P < 0.05] scores also improved in
the darbepoetin-treated patients, remaining unchanged in
the placebo group (except for Zung SDS, which worsened
[49 ± 8 (from 44 ± 10); P < 0.05]. There was also a sig-
nificant correlation between darbepoetin-induced percent
changes in 6MWT and Zung SDS (R =− 0.627, P < 0.05).
Koureaetal.[21]concludedthat,throughameliorationof
symptoms,darbepoetinalfaimprovedthequalityoflifeandFuture perspectives on erythropoiesis-stimulating agents i7
emotional stress of CHF patients with anaemia, with a par-
allel increase in exercise capacity. They felt that short-term
darbepoetinalfaadministrationwasaneffectivetherapeutic
approachtocorrectanaemiaandimprovequalityoflifeand
depressive symptoms in patients with CHF. They also con-
sidered that these beneficial effects might have important
clinical implications, reasoning that the antidepressant ac-
tion of darbepoetin might counteract a pathophysiological
contributor to CHF progression.
In a study of 32 anaemic CHF patients, Parissis and col-
leagues [22] evaluated the effects of darbepoetin alfa on
left (LV) and right ventricular (RV) function and neurohor-
monal activation. Patients were randomized 2:1 to receive
darbepoetin alfa (1.5 μg/kg every 20 days) plus oral iron
(n = 21) or placebo plus oral iron (n = 11), for 3 months.
The F and corresponding P values for the interaction be-
tween time of measurement of the studied variables and
treatment were calculated. Treatment with darbepoetin alfa
led to significant improvements in a number of echocardio-
graphic indices of LV systolic and diastolic function and
RV function. Improvements were recorded in LVEF (F =
22.001, P = 0.001), end-systolic wall stress (ESWS; F =
4.934, P = 0.034), mitral annulus systolic displacement
(F = 6.710, P = 0.015), isovolumic relaxation time (F =
4.909, P = 0.035) and E/e ratio (as a marker of LV filling
pressures; F = 7.833, P = 0.009), compared to placebo.
Improvements were also noted in the RV systolic pressure
(F = 7.715, P = 0.009) as well as tricuspid annulus sys-
tolic displacement and right ventricular ejection fraction
(F = 9.264, P = 0.005). In addition, patients treated with
darbepoetin alfa showed improvements in both the 6MWT
(F = 19.926, P = 0.001) and the NYHA functional class
(F = 14.586, P = 0.001). Darbepoetin treatment also cor-
related with reduced neurohormonal activation in these pa-
tients, as indicated by a significant fall in plasma levels of
BNP (F = 14.781, P = 0.001). This was associated with
reduction of elevated ESWS in these patients, together with
symptomatic improvement. As high plasma levels of BNP
appear to be associated with adverse clinical outcomes in
CHF, this finding may be of clinical importance.
In the multicentre, randomized, double-blind, placebo-
controlled ‘Study of Anaemia in Heart Failure Trial’
(STAMINA-HeFT),theeffectoftreatinganaemiawithdar-
bepoetinalfaoncardiovascularoutcomes,exercisecapacity
and quality of life measures was evaluated in 319 anaemic
patients with symptomatic CHF [23]. Patients were ran-
domized1:1toplaceboors.c.darbepoetinalfaadministered
every 2 weeks for 1 year, with a target Hb level of 14.0 ±
1.0 g/dL. While darbepoetin alfa raised and maintained Hb
levels within the target range, treatment did not signifi-
cantly improve exercise duration, NYHA class or quality
of life score compared with placebo. Interestingly, a non-
significant trend was observed towards a lower risk of all-
cause mortality or first hospitalization due to heart failure
in darbepoetin alfa-treated patients compared with placebo
[hazard ratio 0.68 (95% CI; 0.43–1.08); P = 0.1]. These
data are supportive of the conduct of a larger adequately
powered trial to evaluate the importance of treatment of
anaemia in CHF on cardiovascular outcomes.




Failure (RED-HFTM) trial is a large, double-blind, multi-
centre, randomized, placebo-controlled phase III study to
assess the efficacy and safety of darbepoetin alfa treatment
on morbidity and mortality in patients with symptomatic
LV systolic dysfunction and anaemia (Hb >9.0 g/dL and
<12 g/dL) [24]. Approximately 3400 patients will be ran-
domized 1:1 to receive either darbepoetin alfa or placebo.
Darbepoetin alfa will be initiated at 0.75 μg/kg once every
2 weeks, and will be titrated until the target Hb level of
13.0–14.5 g/dL is achieved. The dose will then be doubled
and the administration interval extended to once monthly.
The primary endpoint is a composite of all-cause death or
first hospitalization for worsening heart failure. The study
is planned to end ∼3 years after the first subject has been
enrolled, when ∼1450 subjects are anticipated to have ex-
perienced a primary endpoint event. The RED-HFTM trial
is anticipated to provide the critical data needed to de-
termine whether treatment of anaemia improves outcomes
in patients with heart failure. The target Hb level in this
trial (13–14.5 g/dL) is no longer in line with the target Hb
range most recently recommended by the EMEA (10–12
g/dL) [13]. However, both the Executive Committee and
the DMC of RED-HFTM are of the opinion that the adverse
findings in CKD patients, from the CREATE and CHOIR
trials, cannot be extrapolated to the RED-HFTM trial [25].
In addition, the positive data already obtained in phase II
trials in CHF provide further support for the continuation
of this study. The DMC has conducted careful and regular
reviews of the safety data from this trial, and will continue
to do so, and has seen no evidence to suggest that the trial
should be stopped due to safety concerns.
U s eo fi . v .i r o ni nt h et r e a t m e n to fa n a e m i ai nC H F
In anaemia of CHF, iron metabolism is disturbed, so it
is possible that administration of iron might improve out-
comes in these patients. In the FERRIC-HF trial, Okonko
and colleagues [26] investigated whether i.v. iron improved
exercise tolerance in 35 anaemic (Hb <12.5 g/dL) or non-
anaemic (Hb 12.5–14.5 g/dL) symptomatic CHF patients
with iron deficiency. Iron loading (200 mg i.v. iron sucrose
per week until ferritin levels were >500 ng/mL and 200
mg i.v. iron monthly thereafter) improved both exercise ca-
pacity and symptoms in patients with CHF, compared with
no treatment. The mean increase in Hb in anaemic patients
was 0.8 g/dL for those treated with i.v. iron versus a 0.6 g/
dL increase in anaemic control patients (P = not sig-
nificant). Overall, mean changes from baseline in abso-
lute pVO2 [+96 (95% CI; −12 to 205) mL/min; P =
0.08], pVO2/kg [+2.2 (95% CI; 0.5–4.0) mL/kg/min; P
= 0.01] and treadmill exercise duration [+60 (95% CI;
−6 to 126) seconds; P = 0.08] were significantly larger
in patients receiving iron compared to patients in the con-
trol group, with the most significant benefits evident in
anaemic patients. In addition, mean changes from baseline
to study end in NYHA functional class and Patient Global
Assessment were greater in the i.v. iron treatment group
than in the placebo group [−0.6 (95% CI; −0.9 to −0.2);i8 S. D. Anker and R. Toto
P = 0.007 and 1.7 (95% CI; 0.7–2.6); P = 0.002, respec-
tively]. Thus, evidence suggests that, in addition to ESA
treatment, the use of i.v. iron in the treatment of anaemia
in CHF patients may also be important to their optimal
management. The ongoing IRON-HF Study is a multicen-
tre, randomized, double-blind, placebo-controlled trial to
assess the effects of oral and i.v. iron supplementation in
heart failure patients with anaemia with a primary efficacy
endpoint of variation of peak oxygen consumption [27].
Conclusion
Evidence indicates that anaemia is a potent risk factor for
mortalityandcardiovascularmorbidityamongpatientswith
CKD. Although not yet conclusive, the available data sug-
gest that anaemia therapy may be beneficial in these pa-
tients. TREAT is designed to provide critical and unbiased
risk/benefit information that is needed to guide medical
practiceinthishigh-riskpopulationandisexpectedtoserve
as an example of a robust randomized clinical trial that pro-
vides informed and data-driven practice patterns for the
benefit of patients with CKD. It is hoped that the ongoing
RED-HFTM trial will also provide definitive data on the
effect of correcting anaemia in patients with CHF.
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